{"doi":"10.1002/cncr.28145","title":"Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy","abstract":"<jats:sec><jats:title>BACKGROUND</jats:title><jats:p>Use of progression‐free survival (PFS) as a clinical trial endpoint in first‐line treatment of patients with metastatic urothelial carcinoma (UC) is attractive, but would be enhanced by establishing a correlation between PFS and overall survival (OS).</jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p>Data was pooled from 7 phase 2 and 3 trials evaluating cisplatin‐based chemotherapy in metastatic UC. An independent cohort of patients enrolled on a phase 3 trial was used for external validation. Landmark analyses for progression at 6 and 9 months after treatment initiation were performed to minimize lead‐time bias. A proportional hazards model was used to assess the utility of PFS for predicting OS.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>A total of 364 patients were included in the initial cohort. The median PFS was 8.21 months (95% confidence interval = 7.43, 8.39) and the median OS was 13.50 months (95% confidence interval = 11.80, 15.67). In the landmark analysis, the median OS for patients who progressed at 6 months was 3.87 months compared with 15.06 months for those patients who did not progress (<jats:italic>P</jats:italic> &lt; .0001) and the median OS for patients who progressed at 9 months was 5.65 months compared with 21.39 months for those patients who did not progress (<jats:italic>P</jats:italic> &lt; .0001). A Fleischer model demonstrated a statistically significant dependent correlation between PFS and OS. The findings were externally validated in an independent cohort.</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS</jats:title><jats:p>PFS at 6 and 9 months predicted OS in this analysis of patients with metastatic UC treated with first‐line cisplatin‐based chemotherapy and could potentially serve as endpoints in (randomized) phase 2 trials to screen the activity of novel regimens. <jats:bold><jats:italic>Cancer</jats:italic> 2013;119:3020—3026</jats:bold>. © <jats:italic>2013 American Cancer Society</jats:italic>.</jats:p></jats:sec>","journal":"Cancer","year":2013,"id":617559,"datarank":0.8313963502592788,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.47171205933952315,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.47171205933952315,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":8,"citers_with_citation_signal":8,"citers_with_endowment":8,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1592707,"name":"Susan Krege","orcid":null,"position":1,"is_corresponding":false},{"id":320530,"name":"Chia‐Chi Lin","orcid":"0009-0006-5084-0819","position":2,"is_corresponding":false},{"id":1592708,"name":"Noah Hahn","orcid":null,"position":3,"is_corresponding":false},{"id":1592709,"name":"Thorsten Ecke","orcid":null,"position":4,"is_corresponding":false},{"id":266855,"name":"Erin Moshier","orcid":"0000-0002-8912-4709","position":5,"is_corresponding":false},{"id":274683,"name":"Guru Sonpavde","orcid":"0000-0002-1010-9611","position":6,"is_corresponding":false},{"id":824336,"name":"James Godbold","orcid":null,"position":7,"is_corresponding":false},{"id":1252281,"name":"William K. Oh","orcid":null,"position":8,"is_corresponding":false},{"id":1592715,"name":"Aristotle Bamias","orcid":null,"position":9,"is_corresponding":false},{"id":65065,"name":"Matthew D. Galsky","orcid":"0000-0001-7655-9378","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-08-03T02:00:51.935273Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}